Low screening adherence
Many women forgo exams due to fear, embarrassment, lack of time, or difficulty accessing services.
CLARA in the SUS
More coverage. Less waiting.
Faster screening for the public health network.
Bring to your state or municipality a modern screening solution, designed to expand women's access to preventive care, reduce bottlenecks in health facilities, and accelerate HPV and STI program coverage.
Learn MoreClara Test supports public health strategies focused on simplified collection, greater adherence, straightforward logistics, and integration with municipal campaigns, UBS, community drives, and primary care programs.
REQUEST A PRESENTATION
Cervical cancer remains
a public health priority
HPV is directly associated with cervical cancer, and
the WHO recommends the use of DNA-HPV testing as a
primary screening strategy for disease
prevention.
The WHO's global strategy also establishes 90-70-90
targets:
90% vaccination, 70% screening coverage, and 90%
treatment for pre-cancerous lesions and invasive cancer
by 2030.
Long queues and unit overload
Traditional collection depends on scheduling, available rooms, staff, and in-person attendance.
Coverage below target
The network needs to reach more women in less time, especially in peripheral, rural, and vulnerable regions.
Late diagnosis costs more
When prevention fails, the system bears higher costs for investigation, treatment, and follow-up.
The solution:
Clara test
Screening with greater reach for public health programs for women.
It is a strategic
solution for:
State Health Departments
Regional screening programs and coverage expansion.
City Halls and Municipal Health Departments
Actions in UBS, women's health campaigns, community drives, and active outreach.
Primary Care Network
Support for health teams, nursing staff, community health agents, and territorial programs.
Public Consortiums and Hospitals
Organization of triage, referral, and follow-up flows.
Aligned with
International
Recommendations
The WHO recommends the DNA-HPV test as a primary screening method for cervical cancer prevention, as it is a high-performance strategy.
Benefits for States and Municipalities
Faster coverage
With a simple, standardized kit, the network can expand campaigns across multiple service points, reducing exclusive dependence on traditional collection rooms.
Expected impact:
More women reached in less time.
Less waiting time
By simplifying the collection step and organizing the triage flow, municipalities reduce bottlenecks in UBS, outpatient clinics, and in-person campaigns.
Expected impact:
Less congested scheduling and more efficient care.
Greater women's adherence
Simplified collection reduces emotional and logistical barriers. This can help women who avoid the exam due to discomfort, embarrassment, or difficulty accessing services.
Expected impact:
Greater participation in women's health campaigns.
Strategy for vulnerable areas
Ideal for campaigns in low-coverage regions, rural areas, remote communities, peripheries, and territories with limited network access.
Expected impact:
More inclusive and territorially grounded public health.
Why choose
Clara Test for
the public health network?
Clara Test can be positioned within a broader public strategy for screening and women's health surveillance, focusing on HPV, STIs, and cervical cancer prevention.
Clara Test delivers a solution with the potential to support public managers on three fronts:
Population coverage
Helps reach more women in preventive programs.
Operational efficiency
Supports reducing bottlenecks in primary care.
Preventive care
Strengthens public policies aligned with the global strategy for cervical cancer elimination.
Cervical cancer and sexually
transmitted
diseases
A critical problem
that needs an
immediate
solution!
Delays in collection and testing are increasingly worsening the current situation. When diagnosis doesn't happen at the right time, simple infections progress, risks of complications grow, and transmission becomes easier. The result is clear: more cases, more complex treatments, and greater impact on public health.
Speed in diagnosis is not a detail —
it's what changes the outcome.
it's what changes the outcome.
Why does this matter?
Many infections are silent
HPV and other STIs may not show obvious signs at first, delaying the search for medical guidance.
Early diagnosis saves time, health, and lives
The sooner a change is identified, the greater the chances of proper follow-up and timely treatment.
Prevention changes the future
Medical follow-up and screening tests are essential steps for reducing risks.
Caring for intimate health should not be
postponed.
Information, prevention, and screening are part of a
safer
and more conscious feminine routine.
Clara Test for Governments
A solution to expand coverage, reduce queues, and strengthen women's health in the SUS.
Talk to our team and learn about the implementation
model for
states, city halls, public consortiums, and municipal
health
networks.